AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02389348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: Single oral doses of OZ439
Study NCT02205190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT02205190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study NCT02205190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Rosuvastatin combination
Study NCT02542293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab +Tremelimumab
Study NCT02542293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + carboplatin
Description: Chemotherapy Agents
Study NCT02542293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin
Description: Chemotherapy Agents
Study NCT02542293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + carboplatin
Description: Chemotherapy Agents
Study NCT02542293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + cisplatin
Description: Chemotherapy Agent
Study NCT02542293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + carboplatin
Description: Chemotherapy Agent
Study NCT03484143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neuro RX Gamma device
Description: Twenty minute treatment session, 6 days a week for 24 weeks
Study NCT03484143 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuro RX Gamma device
Description: Twenty minute treatment session, 6 days a week for 24 weeks
Study NCT01974349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib (oral)
Description: Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
Study NCT01932632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Minimization
Description: Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
Study NCT02738307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
Study NCT05225753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hemoglobin serum value
Description: post-operative anemia evaluated with hemoglobin serum value
Study NCT01261689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine/ Sufentanil according to local hospital protocol
Description: according to local hospital protocol
Study NCT01261689 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care-as usual pain treatment
Description: Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
Study NCT03902457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
Study NCT00177177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnosine (dietary supplement)
Description: an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
Study NCT02101593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study NCT03695952 — intervention group
Intervention type: DRUG
Intervention: Nivolumab or pembrolizumab
Description: Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
Study NCT04152551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate Oral Tablet
Description: Oral bisphosphonate
Study NCT04597125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
Study NCT00177177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-carnosine (dietary supplement)
Description: an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
Study NCT01203293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior based therapy
Description: 15-20 individual psychotherapy sessions
Study NCT03961659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutid
Description: Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study NCT04424628 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radiotherapy A
Description: Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
Study NCT04424628 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radiotherapy B
Description: Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
Study NCT04597125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAH therapy
Description: Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
Study NCT03420404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM physician involved collaborative care model (TCMCMC)
Description: TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total.
Study NCT01637636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, oral capsule, once, Days 1 and 12
Study NCT01637636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, oral capsule, once, Days 1 and 6
Study NCT01637636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
Study NCT01203293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
Study NCT02595346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
Study NCT02595346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
Study NCT01637636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
Study NCT00935350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX
Study NCT00935350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 5.0 grams of PGX
Study NCT00935350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX
Study NCT02975999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Study NCT02975999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Study NCT00085982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
Study NCT03514511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S
Study NCT03961659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study NCT03961659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study NCT02458859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO (single use portable negative pressure wound therapy)
Description: Single use portable negative pressure wound therapy
Study NCT03514511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo
Study NCT04215146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
Study NCT04215146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
Study NCT02211768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI, FDG-PET/CT scans
Description: Standard of care to be obtained as part of the study
Study NCT02211768 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI, FDG-PET/CT scans
Description: Standard of care to be obtained as part of the study
Study NCT02211768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FLT-PET/CT scans
Description: FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
Study NCT04019106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in bovine lipid extract surfactant (BLES)
Description: Budesonide in bovine lipid extract surfactant
Study NCT02776462 — intervention group
Intervention type: DEVICE
Intervention: EyeBox CNS
Study NCT03324334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid antibodies
Description: Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
Study NCT03324334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid sonography
Description: Thyroid sonography to detect anatomical changes in thyroid
Study NCT03053986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple polyphenols
Description: 1 tablet per day at evening before sleeping
Study NCT03053986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day at evening before sleeping
Study NCT01294306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT04215146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
Study NCT04215146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
Study NCT03638726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine sulfate and epinephrine
Description: Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
Study NCT03638726 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical cyclopentolate and phenylephrine
Description: Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
Study NCT02851745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT02851745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02870010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples (5 ml) will be taken
Description: blood samples (5 ml) will be taken
Study NCT02370797 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Fraction IOeRT
Description: A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
Study NCT03660826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03660826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy
Study NCT03660826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT03660826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO
Study NCT03660826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT00053040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cintredekin besudotox
Description: IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
Study NCT03660826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT03660826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03660826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03660826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo
Study NCT01294306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01294306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01294306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03660826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03660826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03187223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
Study NCT03187223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
Study NCT03187223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
Study NCT02870010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
Study NCT02803424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume controlled ventilation
Description: During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
Study NCT02803424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autoflow-volume controlled ventilation
Description: After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
Study NCT04007653 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study NCT04785755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral standard diuretics therapy
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
Study NCT04785755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral standard diuretics therapy
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
Study NCT04085458 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027)
Description: The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
Study NCT02554149 — intervention group
Intervention type: RADIATION
Intervention: Radiological measurement of femoral stem version
Description: particular radiographs( lateral decubitus view) and CT scans
Study NCT06075966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-fusion group
Description: Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
Study NCT06075966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fusion group
Description: Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
Study NCT06075966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fusion group
Description: Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University